Abstract

HIV self-testing (HIVST) devices are acknowledged as having the potential to enable the acceleration of HIV diagnosis and linkage to care. How efficiently professional and trained users engaged with the Asante HIV-1/2 Oral Self-Test (Asante) (Sedia Biosciences, Portland, OR, USA), and the accuracy of the device in comparison to other HIV rapid diagnostic tests (RDT), was assessed to be able to guide the development and adoption of the device in Senegal and South Africa. Using convenience sampling, potential participants were recruited from catchment areas where HIV was prevalent. Trained users performed an HIV test on participants using an Oral HIVST. The professional user’s interpretation of results was then measured against the results of various other RDTs. The South African study had 1652 participants and the Senegalese, 500. Most of the participants in each study were 18–35 years old. Senegal had a higher number of females (346/500, 69.2%) compared to South Africa (699/1662, 42.1%). Asante displayed very high sensitivity and specificity when tested against other devices. In the final enzyme-linked immunosorbent assay (ELISA) comparison, in South Africa, the sensitivity: specificity was 99.1:99.9% and in Senegal, 98.4:100.0%. Senegal further identified 53/63 (84.1%) with HIV-1, 8/63 (12.7) with HIV-2 and 2/63 (3.2%) with HIV-1/2 co-infections. Professional or trained users’ interpretations of Asante results correlated strongly to results when using various RDTs, the ELISA assay and Western blot tests, making it a dependable HIV testing instrument.

Highlights

  • The World Health Organization’s (WHO, Geneva, Switzerland) “Treat All” operation, initiated in 2015, directs that anyone who is HIV-positive is eligible for treatment without any restrictions [1]

  • Candidates werewere enrolled in thein study

  • Just over two-thirds of participants were between years of age

Read more

Summary

Introduction

The World Health Organization’s (WHO, Geneva, Switzerland) “Treat All” operation, initiated in 2015, directs that anyone who is HIV-positive is eligible for treatment without any restrictions [1]. Despite the uptake of this campaign globally, sub-Saharan Africa (SSA). Still displays a substantial number of HIV infections and AIDS-related deaths [2]. The. WHO’s 90-90-90 goal [3] within SSA has not been completely realized [4]. South Africa, while having achieved the first 90—people knowing their HIV status—has fallen short in the other two areas [5]. Senegal has not reached any of the “90” targets [6]. These realities are alarming, for if the issues regarding awareness of one’s HIV status and linkage to care are not hastened, it is uncertain whether countries such as South

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.